HANNARİCİ, Z. Et Al. 2022. Lipegfilgrastim may cause hyperleukocytosis. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.8 , 1902-1905.

HANNARİCİ, Z., YILMAZ, A., Buyukbayram, M. E., TURHAN, A., TEKİN, S. B., & BİLİCİ, M., (2022). Lipegfilgrastim may cause hyperleukocytosis. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.8, 1902-1905.

HANNARİCİ, Zekeriya Et Al. "Lipegfilgrastim may cause hyperleukocytosis," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.8, 1902-1905, 2022

HANNARİCİ, Zekeriya Et Al. "Lipegfilgrastim may cause hyperleukocytosis." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.8, pp.1902-1905, 2022

HANNARİCİ, Z. Et Al. (2022) . "Lipegfilgrastim may cause hyperleukocytosis." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.8, pp.1902-1905.

@article{article, author={Zekeriya HANNARİCİ Et Al. }, title={Lipegfilgrastim may cause hyperleukocytosis}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2022, pages={1902-1905} }